Food for thought with CCP:
Annual FY operating costs are around $2.5 ~ $3M. (Lets use the lower $2.5M in this analysis)
Smart tags sold via channel partners generate $120 pa.
While smart tags sold directly are priced at $180.
The companies direction is to leverage their channel partners at I think 65/35 ratio so lets average a smart tag at $145 pa.
So to reach break even we need to sell over 17 thousand smart tags.
Our current CCV is $730k so we have around 5,000 active smart tags in active subscription.
So we need 350% growth on our current subscription amount to break even.
Below is the CCV growth from Q1 2017 to now.
Column 1 Column 2 Column 3 Column 4 Column 5 Column 6 Column 7 Column 8 Column 9 Column 10 Column 11 Column 12 Column 13 Column 14 0 Customer Contract Value (CCV) Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 2020 1 24 Month CCV $ 275,000 $ 340,000 $ 440,000 $ 530,000 $ 630,000 $ 750,000 $ 900,000 $ 1,080,000 $ 1,296,000 $ 1,555,200 $ 1,866,240 $ 2,239,488 $ 2,687,386 2 Increase 24% 29% 20% 19% 19% 20% 20% 20% 20% 20% 20% 20%
We are growing CCV at about 20% average each quarter.
Assuming all stays as is we are pretty far away from returning a net profit.
But realistically we know the company will sign more channel partners and expand into new geographies/countries and the technology is 'morphing' to target new markets as we have seen with these new Ph sensors and so forth.
So in my 'optimistic' model I see us break even 1H 2019.
Column 1 Column 2 Column 3 Column 4 Column 5 Column 6 Column 7 Column 8 Column 9 Column 10 0 Customer Contract Value (CCV) Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 1 24 Month CCV $ 275,000 $ 340,000 $ 440,000 $ 530,000 $ 630,000 $ 819,000 $ 1,064,700 $ 1,597,050 $ 2,395,575 2 Increase 24% 29% 20% 19% 30% 30% 50% 50%
Pure speculation and of course have assumed Opex stays flat.
Just food for thought and I also think CCP are selling the devices too cheap, unless we make a significant footprint globally.
- Forums
- ASX - By Stock
- CT1
- Ann: Response to Appendix 4C Query
Ann: Response to Appendix 4C Query, page-12
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CT1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.474M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
31 | 23495490 | 0.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.2¢ | 222518 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 187500 | 0.008 |
4 | 660631 | 0.007 |
2 | 1091666 | 0.006 |
2 | 1266959 | 0.005 |
1 | 150000 | 0.004 |
Price($) | Vol. | No. |
---|---|---|
0.009 | 47144 | 1 |
0.010 | 1000000 | 1 |
0.012 | 305828 | 1 |
0.013 | 159960 | 1 |
0.014 | 71499 | 1 |
Last trade - 16.12pm 25/11/2024 (20 minute delay) ? |
Featured News
CT1 (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online